Clinical Trials Directory

Trials / Conditions / Schistosomiasis

Schistosomiasis

54 registered clinical trials studyying Schistosomiasis5 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingPrevalence and Molecular Identification of Human Schistosomiasis
NCT07482215
Assiut University
RecruitingRisk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
NCT07358910
Institut Pasteur du Cambodge
Not Yet RecruitingFemale Genital Schistosomiasis in Migrant Women: A Pilot Study
NCT06828536
Assistance Publique - Hôpitaux de ParisN/A
RecruitingIntroduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Are
NCT06698510
Peter Steinmann
UnknownSm-p80 Schistosomiasis Challenge Study
NCT05999825
Leiden University Medical CenterPhase 2
RecruitingAssessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis
NCT06873308
IRCCS Sacro Cuore Don Calabria di NegrarN/A
UnknownEffectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control
NCT06182176
London School of Hygiene and Tropical MedicineN/A
Active Not RecruitingEvaluation of a Comprehensive School Health Programme in Zambia
NCT06560853
London School of Economics and Political ScienceN/A
CompletedHealth Education Model Led by Community Health Volunteers.
NCT06312462
Pemba Ministry of Health ZanzibarN/A
CompletedDelivering a Multi-disease Screening Tool to Migrant Populations
NCT05868005
Barcelona Institute for Global HealthN/A
CompletedA Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candi
NCT05762393
International Vaccine InstitutePhase 1
UnknownFeasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children
NCT05354258
London School of Hygiene and Tropical MedicineN/A
CompletedSafety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
NCT05292391
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedRetrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France
NCT04810741
Assistance Publique - Hôpitaux de Paris
CompletedRepeated Controlled Human Schistosoma Mansoni Infection
NCT05085470
Leiden University Medical CenterN/A
UnknownPraziquantel in Children Under Age 4
NCT03640377
Rhode Island HospitalPhase 2
UnknownSelexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
NCT04589390
University of Sao Paulo General HospitalPhase 2
CompletedSingle-sex Female Controlled Human Schistosomiasis Mansoni Infection
NCT04269915
Leiden University Medical CenterN/A
UnknownMonitoring Schistosome Hybrids Under Under Praziquantel Pressure
NCT04635553
Institut de Recherche pour le Developpement
CompletedSm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
NCT03910972
Baylor College of MedicinePhase 1 / Phase 2
CompletedTreatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study
NCT04115072
Regionshospital NordjyllandPhase 2 / Phase 3
CompletedL-PZQ ODT in Schistosoma Infected Children
NCT03845140
Merck KGaA, Darmstadt, GermanyPhase 3
CompletedAnti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
NCT03799510
Oswaldo Cruz FoundationPhase 2
CompletedRepeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
NCT02868385
Leiden University Medical CenterPhase 3
CompletedA Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without
NCT03110757
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
TerminatedSeropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas
NCT03158298
Jena University Hospital
UnknownSchistosomiasis in Senegal
NCT03187366
University of Notre DameN/A
CompletedStudy of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions
NCT03041766
Oswaldo Cruz FoundationPhase 2
CompletedSingle-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
NCT02755324
Leiden UniversityN/A
CompletedAn Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Manson
NCT02806232
Merck KGaA, Darmstadt, GermanyPhase 2
WithdrawnEffect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquante
NCT02734186
National Institute of Allergy and Infectious Diseases (NIAID)Phase 4
CompletedChildhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment
NCT02495909
University of Edinburgh
CompletedA Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-
NCT02337855
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedDetection of Schistosomiasis CAA in Travellers After High-risk Water Contact
NCT02194712
Meta Roestenberg
CompletedDiagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
NCT02105714
Swiss Tropical & Public Health Institute
CompletedArachidonic Acid Treatment Against Schistosomiasis Infection in Children
NCT02144389
dsm-firmenich Switzerland AGN/A
UnknownEvaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis
NCT01869465
Makerere UniversityN/A
CompletedHealth Benefits of Repeated Treatment in Pediatric Schistosomiasis
NCT01424410
University of Edinburgh
CompletedPraziquantel-Pharmacokinetic Study
NCT01288872
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedSchistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
NCT01553552
Biomedical Research Center EPLS
CompletedStudy to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
NCT01154049
Oswaldo Cruz FoundationPhase 1
CompletedPrevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa
NCT03458338
University Hospital, Basel, Switzerland
UnknownArtemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren i
NCT01459146
Navrongo Health Research Centre, GhanaPhase 4
CompletedCorrelating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
NCT01214876
Radboud University Medical Center
UnknownAntioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis
NCT01260012
Addis Ababa UniversityN/A
CompletedSchistosoma Haematobium Infections and Praziquantel
NCT01558336
University of KhartoumPhase 3
CompletedS. Japonicum and Pregnancy Outcomes
NCT00486863
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
CompletedSchistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control
NCT00463632
DBL -Institute for Health Research and Development
CompletedWomen and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina F
NCT00463528
DBL -Institute for Health Research and Development
CompletedSchistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes
NCT00463593
DBL -Institute for Health Research and Development
CompletedUsing Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatme
NCT00463931
DBL -Institute for Health Research and Development
CompletedThe Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Ug
NCT00215267
DBL -Institute for Health Research and DevelopmentN/A
CompletedIron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
NCT00276224
DBL -Institute for Health Research and DevelopmentN/A
CompletedClinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
NCT01512277
University Hospital, LillePhase 1